UK shareholder meetings calendar - next 7 days
13th May 2022 16:01
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday: Read More
(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point. Read More
(Alliance News) - Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy. Read More
(Alliance News) - Stock prices in London opened sharply higher on Thursday after the US Federal reserve assuaged fears over further aggressive monetary policy tightening, while positive updates from Mondi and Shell boosted the FTSE 100. Read More
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. Read More
(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed. Read More
(Alliance News) - Hikma Pharmaceuticals PLC said on Friday that both its Injectables and Branded businesses have performed well at the start of the year but noted its Generics business has experienced some headwinds. Read More
(Alliance News) - Educational materials publisher Pearson on Friday provided a positive update on first quarter trading, while also announcing a new acquisition. Read More
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to USD425 million. Deal will add up to 13 approved products and additional pipeline products. Read More
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More
(Alliance News) - London Stock Exchange Group on Thursday said 2021 was a successful year following the acquisition of Refinitiv, leaving the stock exchange operator well positioned as a financial market infrastructure and data business. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: Read More
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase will begin on Friday and end by June 25. Hikma had announced the buyback programme with its annual results, saying it reflected its strong cash generation, balance sheet strength, and confidence in future growth prospects. Hikma also had declared a final dividend of 36 cents, a 5.9% boost from a shareholder payout of 34 cents the year before. Its full-year dividend amounted to 54 US cents, up 8.0% from 50 cents. Read More
(Alliance News) - International Consolidated Airlines Group on Friday posted a narrowed loss for 2021, saying that after the setback caused by Omicron at the end of the year, bookings have rebounded strongly and it expects to fly 85% of its 2019 capacity in 2022. Read More
(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout. Read More